SAN DIEGO, March 17, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today announced it expects to report fourth quarter and full year 2010 financial results after the NASDAQ Global Market closes on Wednesday, March 23, 2011. The Company also expects to host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and highlights for the fourth quarter and full year 2010 and to provide a corporate update.

The conference call may be accessed by dialing (877) 845-0779 for domestic callers and (760) 298-5087 for international callers. Please specify to the operator that you would like to join the "Trius Financial Results Call." The conference call will be webcast live under the Investors section of Trius' website at http://investor.triusrx.com/ , where it will be archived for 30 days following the call. Please connect to Trius' website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead investigational drug, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com .
CONTACT: Public Relations Contact:         Jason Spark at Canale Communications, Inc.         jason@canalecomm.com         619-849-6005                  Investor Relations Contact:         Stefan Loren at Westwicke Partners, LLC         sloren@westwicke.com         443-213-0507

If you liked this article you might like

Cramer's 'Mad Money' Recap: Disciplined Investors Rule

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Cramer Quick Take: What's Next for Biotech?

Morning Briefing: 10 Things You Should Know

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys